FORMULATION AND EVALUATION OF PRESSED COATED TABLETS OF DICLOFENAC POTASSIUM
R. R. Thenge*, G. D. Mehetre and V. S. Adhao
ABSTRACT
The main objective of the studies described was to develop a time-controlled release formulation based on a press-coating technique. The intention was that the formulation is administered in the evening at 22:00, which provides treatment for diseases in which symptoms are experienced in the early morning hours (i.e. chronopharmacotherapy). The Diclofenac potassium pressed coated tablets were prepared using direct compression method. The coats contained a hydrophilic polymer (hydroxypropylmethylcellulose) to control drug release. Cores were immediate-release formulations containing all or most of the drug dose. The time-controlled release dosage form containing HPMC allows time to peak plasma level to be adjusted to 6 to 8 hours after administration. Amount of HPMC used, HPMC viscosity grades selected were most important factors controlling drug release and absorption from the dosage form. The pressed coated tablets were evaluated for post compression studies such as hardness, friability, drug content, weight variation and dissolution studies. The kinetic data also applied to the dissolution. All the prepared tablets formulations were found to be good without capping and chipping. Post Compressionalparameters (hardness, friability, thickness and drug content) was within the acceptable limit. FTIR Spectroscopicstudies indicated that the drug is compatible with all the excipients. The in vitro drug release of polymer coated tablet of Diclofenac Potassium prepared by direct compression F2 method were found to be 96.60% at 8 hrs. Among the all formulations F2 formulation was found to be promising with controlled drug release. The inner Core tablets prepared with Superdisintegrant exhibited good disintegration characteristics. tablets having CP as the disintegrant showed faster dissolution rates and higher efficiency values.
Keywords: Diclofenac potassium, Compression coated, Tablets, FTIR, HPMC, Crosspovidone.
[Full Text Article]
[Download Certificate]
SJIF Impact Factor: 7.065
